{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:56:32Z","timestamp":1793876192505,"version":"4.7.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.amjcard.2025.09.039","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:26:20Z","timestamp":1759011980000},"page":"268-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With Diabetes and Peripheral Artery Disease: An Updated Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"258","author":[{"given":"Syed Hasan","family":"Shuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-7298","authenticated-orcid":false,"given":"Muhammad Hamza","family":"Shuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Shaukat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramish","family":"Hannat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilsa","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siad","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelkhalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mah I Kan","family":"Changez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-7810","authenticated-orcid":false,"given":"Bernardo","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjcard.2025.09.039_bib0001","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0781-1","article-title":"Lower extremity arterial disease in patients with diabetes: a contemporary narrative review","volume":"17","author":"Nativel","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.amjcard.2025.09.039_bib0002","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01401-8","article-title":"Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression","volume":"20","author":"Maiorino","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"25","key":"10.1016\/j.amjcard.2025.09.039_bib0003","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1016\/j.jacc.2018.04.027","article-title":"Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus","volume":"71","author":"Liu","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10226","key":"10.1016\/j.amjcard.2025.09.039_bib0004","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155\u2008722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study","volume":"395","author":"Yusuf","year":"2020","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.amjcard.2025.09.039_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1545","article-title":"Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease: the STARDUST randomized clinical trial","volume":"7","author":"Caruso","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"15","key":"10.1016\/j.amjcard.2025.09.039_bib0006","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1042\/CS20171299","article-title":"Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review","volume":"132","author":"Boyle","year":"2018","journal-title":"Clin Sci"},{"issue":"2","key":"10.1016\/j.amjcard.2025.09.039_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11906-015-0621-6","article-title":"GLP-1 agonists and blood pressure: a review of the evidence","volume":"18","author":"Goud","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.amjcard.2025.09.039_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102789","article-title":"GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review","volume":"75","author":"Jarade","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.amjcard.2025.09.039_bib0009","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjcard.2025.09.039_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2025.09.039_bib0011","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised cochrane risk-of-bias tool for randomized trials | Cochrane Bias. [Accessed on 2025 May 23]. Available at: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials"},{"issue":"7414","key":"10.1016\/j.amjcard.2025.09.039_bib0012","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"issue":"7","key":"10.1016\/j.amjcard.2025.09.039_bib0013","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","volume":"24","author":"Verma","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"10489","key":"10.1016\/j.amjcard.2025.09.039_bib0014","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"The Lancet"},{"issue":"10157","key":"10.1016\/j.amjcard.2025.09.039_bib0015","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.amjcard.2025.09.039_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","article-title":"Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: results from the EXSCEL trial","volume":"12","author":"Badjatiya","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.amjcard.2025.09.039_bib0017","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1097\/MJT.0000000000001689","article-title":"Cardiovascular safety of glucagon-like receptor 1 agonists in patients with type 2 diabetes and peripheral arterial disease: a meta-analysis of randomized controlled trials","volume":"31","author":"Ashraf","year":"2024","journal-title":"Am J Ther"},{"key":"10.1016\/j.amjcard.2025.09.039_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","author":"Ferhatbegovi\u0107","year":"2023","journal-title":"Front Clin Diabetes Healthcare"},{"issue":"9","key":"10.1016\/j.amjcard.2025.09.039_bib0019","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/medicina60091542","article-title":"Cardiovascular Effectiveness and safety of antidiabetic drugs in patients with type 2 diabetes and peripheral artery disease: systematic review","volume":"60","author":"Cimellaro","year":"2024","journal-title":"Medicina."},{"key":"10.1016\/j.amjcard.2025.09.039_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2025.05.037","article-title":"GLP-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate PAD","author":"Go","year":"2025","journal-title":"J Vasc Surg"},{"issue":"16","key":"10.1016\/j.amjcard.2025.09.039_bib0021","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/jcm13164674","article-title":"Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs","volume":"13","author":"Le","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.amjcard.2025.09.039_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2040622317735283","article-title":"Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential","volume":"9","author":"R\u00f8der","year":"2017","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.amjcard.2025.09.039_bib0023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2022.06.1022","article-title":"Percutaneous coronary intervention with peripheral artery disease in the contemporary era: still life or limb?","volume":"355","author":"Kumar","year":"2022","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.amjcard.2025.09.039_bib0024","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s13300-018-0524-z","article-title":"Liraglutide and glycaemic outcomes in the LEADER trial","volume":"9","author":"Zinman","year":"2018","journal-title":"Diabetes Therapy"},{"issue":"7","key":"10.1016\/j.amjcard.2025.09.039_bib0025","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjcard.2025.09.039_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108390","article-title":"Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review","volume":"37","author":"Liarakos","year":"2023","journal-title":"J Diabetes Complications"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925005958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925005958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T01:27:47Z","timestamp":1765070867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925005958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"alternative-id":["S0002914925005958"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.09.039","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With Diabetes and Peripheral Artery Disease: An Updated Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.09.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}